Importantly, ZMYND11 was consistently downregulated in metastatic samples from several independent human prostate cancer clinical datasets41–44 (Fig. 1b and Supplementary Fig. 1b), and its downregulation was notably correlated with high Gleason scores, advanced tumor stages, and elevated prostate-specific antigen (PSA) levels45–47 (Fig. 1c and Supplementary Fig. 1c). The gene discussed is KLK3; the disease is prostate cancer.